688317 之江生物
已收盘 12-15 15:00:01
资讯
新帖
简况
之江生物（688317）披露关于开立募集资金专户并签订募集资金专户监管协议的公告，12月9日股价下跌1.32%
证券之星 · 12-09
之江生物（688317）披露关于开立募集资金专户并签订募集资金专户监管协议的公告，12月9日股价下跌1.32%
之江生物（688317）披露回购股份进展公告，12月2日股价下跌1.56%
证券之星 · 12-02
之江生物（688317）披露回购股份进展公告，12月2日股价下跌1.56%
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，11月24日股价上涨2.08%
证券之星 · 11-24
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，11月24日股价上涨2.08%
每周股票复盘：之江生物（688317）股东会通过外汇衍生品交易议案
证券之星 · 11-16
每周股票复盘：之江生物（688317）股东会通过外汇衍生品交易议案
之江生物（688317）披露公司开展外汇衍生品交易业务议案获股东会通过，11月14日股价上涨3.07%
证券之星 · 11-14
之江生物（688317）披露公司开展外汇衍生品交易业务议案获股东会通过，11月14日股价上涨3.07%
之江生物（688317）披露首次回购股份进展，11月03日股价下跌0.91%
证券之星 · 11-03
之江生物（688317）披露首次回购股份进展，11月03日股价下跌0.91%
三友生物与之江生物签署创新生物医药自动化研发战略合作协议
美股速递 · 11-03
三友生物与之江生物签署创新生物医药自动化研发战略合作协议
之江生物(688317.SH)取得一项医疗器械注册证
智通财经 · 11-03
之江生物(688317.SH)取得一项医疗器械注册证
每周股票复盘：之江生物（688317）股东户数下降7.74%，公司拟回购6000万至1.2亿元股份
证券之星 · 11-02
每周股票复盘：之江生物（688317）股东户数下降7.74%，公司拟回购6000万至1.2亿元股份
之江生物（688317）2025年三季报简析：净利润同比下降125.82%，三费占比上升明显
证券之星 · 10-31
之江生物（688317）2025年三季报简析：净利润同比下降125.82%，三费占比上升明显
之江生物(688317.SH)发布前三季度业绩，归母净亏损2938万元
智通财经 · 10-29
之江生物(688317.SH)发布前三季度业绩，归母净亏损2938万元
之江生物(688317)9月30日股东户数1.44万户，较上期减少7.74%
证券之星 · 10-29
之江生物(688317)9月30日股东户数1.44万户，较上期减少7.74%
之江生物（688317）披露2025年第三次以集中竞价交易方式回购股份计划，10月27日股价上涨0.8%
证券之星 · 10-27
之江生物（688317）披露2025年第三次以集中竞价交易方式回购股份计划，10月27日股价上涨0.8%
每周股票复盘：之江生物（688317）回购股份事项股东持股情况公布
证券之星 · 10-26
每周股票复盘：之江生物（688317）回购股份事项股东持股情况公布
之江生物（688317）披露回购股份事项前十名股东持股情况，10月23日股价下跌1.14%
证券之星 · 10-23
之江生物（688317）披露回购股份事项前十名股东持股情况，10月23日股价下跌1.14%
之江生物最新公告：拟以6000万元至1.2亿元回购股份
证券之星 · 10-16
之江生物最新公告：拟以6000万元至1.2亿元回购股份
每周股票复盘：之江生物（688317）开立募资专户推进日本项目
证券之星 · 09-28
每周股票复盘：之江生物（688317）开立募资专户推进日本项目
之江生物（688317）披露开立募集资金专户并签订监管协议公告，9月26日股价下跌1.05%
证券之星 · 09-26
之江生物（688317）披露开立募集资金专户并签订监管协议公告，9月26日股价下跌1.05%
每周股票复盘：之江生物（688317）产品列入WHO应急使用清单
证券之星 · 09-21
每周股票复盘：之江生物（688317）产品列入WHO应急使用清单
之江生物（688317）自愿披露公司产品列入WHO应急使用清单，9月18日股价下跌1.67%
证券之星 · 09-18
之江生物（688317）自愿披露公司产品列入WHO应急使用清单，9月18日股价下跌1.67%
加载更多
公司概况
公司名称：
上海之江生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-18
主营业务：
上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂和仪器设备。公司共有500多项产品，已形成20大系列，是国内感染性疾病分子诊断产品最为齐全的企业之一，覆盖了绝大多数国家法定传染病。
发行价格：
43.22
{"stockData":{"symbol":"688317","market":"SH","secType":"STK","nameCN":"之江生物","latestPrice":20.18,"timestamp":1765782001000,"preClose":20.12,"halted":0,"volume":863169,"delay":0,"changeRate":0.003,"floatShares":192000000,"shares":192000000,"eps":-0.7486,"marketStatus":"已收盘","change":0.06,"latestTime":"12-15 15:00:01","open":20.06,"high":20.32,"low":20.01,"amount":17424200,"amplitude":0.0154,"askPrice":20.18,"askSize":4,"bidPrice":20.16,"bidSize":198,"shortable":0,"etf":0,"ttmEps":-0.7486,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"adjPreClose":20.12,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":22.13,"lowLimit":18.11,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":192157999,"isCdr":false,"pbRate":1.14,"roa":"--","roe":"--","epsLYR":-0.67,"committee":0.147392,"marketValue":3878000000,"turnoverRate":0.0045,"status":0,"afterMarket":{"amount":0,"volume":0,"close":20.18,"buyVolume":0,"sellVolume":0,"time":1765784037768,"indexStatus":"已收盘 12-15 15:30:00","preClose":20.12},"floatMarketCap":3878000000},"requestUrl":"/m/hq/s/688317","defaultTab":"news","newsList":[{"id":"2590312322","title":"之江生物（688317）披露关于开立募集资金专户并签订募集资金专户监管协议的公告，12月9日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590312322?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:50","pubTimestamp":1765273842,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，之江生物报收于20.88元，较前一交易日下跌1.32%，最新总市值为40.12亿元。该股当日开盘21.12元，最高21.25元，最低20.88元，成交额达1820.25万元，换手率为0.45%。公司近日发布公告称，为规范募集资金管理，保护投资者权益，上海之江生物科技股份有限公司已开立募集资金专户并签订《募集资金专户存储四方监管协议》。公司、子公司、招商银行及保荐机构国泰海通证券共同签署监管协议，明确各方责任与义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900028193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2588313380","title":"之江生物（688317）披露回购股份进展公告，12月2日股价下跌1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588313380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588313380?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:54","pubTimestamp":1764669289,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，之江生物报收于21.47元，较前一交易日下跌1.56%，最新总市值为41.26亿元。该股当日开盘21.91元，最高21.91元，最低21.4元，成交额达2100.39万元，换手率为0.51%。公司近日发布关于2025年第三次以集中竞价交易方式回购公司股份的进展公告。截至2025年11月28日，公司累计回购股份1,093,704股，占总股本0.57%，已支付金额24,160,914.13元，回购价格区间为21.52元/股至22.86元/股。本次回购符合相关规定及方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200027316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2585009468","title":"之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，11月24日股价上涨2.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585009468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585009468?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:00","pubTimestamp":1763978449,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，之江生物报收于21.64元，较前一交易日上涨2.08%，最新总市值为41.58亿元。公司近日发布《关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》。公告显示，截至2025年11月21日，之江生物通过集中竞价交易方式累计回购股份1,012,181股，占公司当前总股本的0.53%。公司于2025年10月15日召开董事会审议通过回购方案，拟用于员工持股计划或股权激励，回购期限为2025年10月15日至2026年10月14日，预计回购金额为6,000万元至12,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2583541826","title":"每周股票复盘：之江生物（688317）股东会通过外汇衍生品交易议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2583541826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583541826?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:57","pubTimestamp":1763240227,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，之江生物报收于23.5元，较上周的22.11元上涨6.29%。本周，之江生物11月14日盘中最高价报23.95元。本周关注点公司公告汇总：之江生物2025年第二次临时股东会审议通过《关于开展外汇衍生品交易业务的议案》，同意票占有效表决权股份总数的99.52%。浙江天册律师事务所确认会议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2583686507","title":"之江生物（688317）披露公司开展外汇衍生品交易业务议案获股东会通过，11月14日股价上涨3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583686507?lang=zh_cn&edition=full","pubTime":"2025-11-14 23:01","pubTimestamp":1763132468,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，之江生物报收于23.5元，较前一交易日上涨3.07%，最新总市值为45.16亿元。该股当日开盘22.81元，最高23.95元，最低22.7元，成交额达1.02亿元，换手率为2.25%。近日，之江生物发布2025年第二次临时股东会决议公告，宣布审议通过《关于开展外汇衍生品交易业务的议案》。出席本次股东会的股东共112人，代表表决权72,821,903股，占公司总表决权的41.1290%。议案获得普通决议通过，且对中小投资者进行了单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2580143022","title":"之江生物（688317）披露首次回购股份进展，11月03日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580143022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580143022?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:36","pubTimestamp":1762180592,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，之江生物报收于22.76元，较前一交易日下跌0.91%，最新总市值为43.74亿元。截至2025年10月31日，公司暂未实施回购。本次回购符合相关规定及公司回购方案。公司将根据市场情况择机实施回购，并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300036284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"1110221438","title":"三友生物与之江生物签署创新生物医药自动化研发战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1110221438","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110221438?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:16","pubTimestamp":1762179368,"startTime":"0","endTime":"0","summary":"三友生物与之江生物签署创新生物医药自动化研发战略合作协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2580307295","title":"之江生物(688317.SH)取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2580307295","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580307295?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:59","pubTimestamp":1762163971,"startTime":"0","endTime":"0","summary":"智通财经APP讯，之江生物(688317.SH)公告，公司1项产品于近期获得国家三类医疗器械注册证，产品名称为：新型冠状病毒2019-nCoV核酸检测试剂盒(荧光PCR法)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK0239","688317","09997","BK1100","09996","BK1222","BK1583","BK1574"],"gpt_icon":0},{"id":"2580472073","title":"每周股票复盘：之江生物（688317）股东户数下降7.74%，公司拟回购6000万至1.2亿元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2580472073","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580472073?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:05","pubTimestamp":1762038316,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，之江生物报收于22.97元，较上周的22.52元上涨2.0%。本周，之江生物10月27日盘中最高价报23.08元。公司公告汇总：之江生物拟回购股份，金额不低于6,000万元且不超过12,000万元。股本股东变化截至2025年9月30日，之江生物股东户数为1.44万户，较6月30日减少1211.0户，减幅为7.74%。预计回购股份数量157.94万股至315.87万股，占总股本比例0.82%至1.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2579092571","title":"之江生物（688317）2025年三季报简析：净利润同比下降125.82%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2579092571","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579092571?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:28","pubTimestamp":1761863310,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期之江生物发布2025年三季报。截至本报告期末，公司营业总收入9043.29万元，同比下降34.27%，归母净利润-2937.79万元，同比下降125.82%。按单季度数据看，第三季度营业总收入3074.98万元，同比下降28.46%，第三季度归母净利润-1952.69万元，同比上升49.95%。本报告期之江生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达93.98%。目前已成功筛选抗体药物分子若干，其中1项进入发明专利受理阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100008231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317"],"gpt_icon":0},{"id":"2579976646","title":"之江生物(688317.SH)发布前三季度业绩，归母净亏损2938万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579976646","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579976646?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:18","pubTimestamp":1761733083,"startTime":"0","endTime":"0","summary":"智通财经APP讯，之江生物(688317.SH)披露2025年第三季度报告，公司前三季度实现营收9043万元，同比下降34.27%;归母净利润亏损2938万元;扣非净利润亏损3725万元;基本每股收益-0.16元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"之江生物(688317.SH)发布前三季度业绩，归母净亏损2938万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2579920760","title":"之江生物(688317)9月30日股东户数1.44万户，较上期减少7.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579920760","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579920760?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:22","pubTimestamp":1761729748,"startTime":"0","endTime":"0","summary":"证券之星消息，近日之江生物披露，截至2025年9月30日公司股东户数为1.44万户，较6月30日减少1211.0户，减幅为7.74%。在医疗器械行业个股中，之江生物股东户数低于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.15万户。从股价来看，2025年6月30日至2025年9月30日，之江生物区间涨幅为28.91%，在此期间股东户数减少1211.0户，减幅为7.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900035667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2578409096","title":"之江生物（688317）披露2025年第三次以集中竞价交易方式回购股份计划，10月27日股价上涨0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578409096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578409096?lang=zh_cn&edition=full","pubTime":"2025-10-27 22:33","pubTimestamp":1761575619,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘，之江生物报收于22.7元，较前一交易日上涨0.8%，最新总市值为43.62亿元。近日，之江生物发布《关于2025年第三次以集中竞价交易方式回购股份的回购报告书》。公告显示，公司拟通过集中竞价交易方式回购股份，回购金额不低于6,000万元且不超过12,000万元，资金来源为自有资金和股票回购专项贷款。预计回购股份数量157.94万股至315.87万股，占公司总股本比例0.82%至1.64%。若三年内未转让回购股份，将依法注销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700036809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2578637507","title":"每周股票复盘：之江生物（688317）回购股份事项股东持股情况公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2578637507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578637507?lang=zh_cn&edition=full","pubTime":"2025-10-26 03:42","pubTimestamp":1761421332,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，之江生物报收于22.52元，较上周的22.78元下跌1.14%。本周，之江生物10月20日盘中最高价报23.28元。本周关注点公司公告汇总：之江生物公布回购股份事项前十名股东持股情况，上海之江药业有限公司持股占比33.81%。根据相关规定，现披露截至2025年10月16日公司前十名股东及前十名无限售条件股东持股情况。前十名股东中，上海之江药业有限公司持股64,969,560股，占比33.81%；公司回购专用证券账户持股14,638,308股，占比7.62%；其余股东持股比例均低于3.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2577378585","title":"之江生物（688317）披露回购股份事项前十名股东持股情况，10月23日股价下跌1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577378585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577378585?lang=zh_cn&edition=full","pubTime":"2025-10-23 22:40","pubTimestamp":1761230425,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘，之江生物报收于22.62元，较前一交易日下跌1.14%，最新总市值为43.47亿元。公司近日发布公告称，为实施以集中竞价交易方式回购股份的方案，现披露截至2025年10月16日公司前十名股东和前十名无限售条件股东的持股情况。公告显示，上海之江药业有限公司持有64,969,560股，占总股本的33.81%；公司回购专用证券账户持有14,638,308股，占总股本的7.62%；其余股东持股比例均低于3.2%。前十名无限售条件股东持股情况与前十名股东一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300038068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2575712959","title":"之江生物最新公告：拟以6000万元至1.2亿元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2575712959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575712959?lang=zh_cn&edition=full","pubTime":"2025-10-16 18:21","pubTimestamp":1760610067,"startTime":"0","endTime":"0","summary":"之江生物(688317.SH)公告称，公司拟通过集中竞价交易方式回购部分已发行的普通股（A股）股份，回购金额不低于6000万元，不超过1.2亿元。资金来源为自有资金和股票回购专项贷款资金。回购价格不超过37.99元/股，回购股份拟用于员工持股计划或股权激励。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101600030421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2570918478","title":"每周股票复盘：之江生物（688317）开立募资专户推进日本项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2570918478","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570918478?lang=zh_cn&edition=full","pubTime":"2025-09-28 02:40","pubTimestamp":1758998419,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，之江生物报收于22.7元，较上周的24.88元下跌8.76%。本周，之江生物9月22日盘中最高价报24.92元。本周关注点公司公告汇总：之江生物开立募集资金专户，用于“日本智能化制造项目”，专户余额为0万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800000627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2570882977","title":"之江生物（688317）披露开立募集资金专户并签订监管协议公告，9月26日股价下跌1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570882977","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570882977?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:28","pubTimestamp":1758896908,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，之江生物报收于22.7元，较前一交易日下跌1.05%，最新总市值为43.62亿元。近日，之江生物发布公告称，为规范募集资金管理，公司已在招商银行股份有限公司上海浦东大道支行开立募集资金专项账户，用于“日本智能化制造项目”的资金存储与使用。公司、招商银行上海浦东大道支行及保荐机构国泰海通证券已共同签署《募集资金专户存储三方监管协议》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600039051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2569464512","title":"每周股票复盘：之江生物（688317）产品列入WHO应急使用清单","url":"https://stock-news.laohu8.com/highlight/detail?id=2569464512","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569464512?lang=zh_cn&edition=full","pubTime":"2025-09-21 04:35","pubTimestamp":1758400512,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，之江生物报收于24.88元，较上周的25.62元下跌2.89%。本周，之江生物9月15日盘中最高价报26.59元。本周关注点公司公告汇总：之江生物猴痘病毒检测试剂盒列入WHO应急使用清单。之江生物猴痘病毒核酸检测试剂盒于2025年9月17日被列入世界卫生组织应急使用清单，申请号MPXV-13393-139-00，产品编码W-ZD-0580-02-48A、W-ZD-0580-02-96A，采购期限原则上为1年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2568740695","title":"之江生物（688317）自愿披露公司产品列入WHO应急使用清单，9月18日股价下跌1.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568740695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568740695?lang=zh_cn&edition=full","pubTime":"2025-09-18 22:55","pubTimestamp":1758207319,"startTime":"0","endTime":"0","summary":"截至2025年9月18日收盘，之江生物报收于24.69元，较前一交易日下跌1.67%，最新总市值为47.44亿元。近日，之江生物发布关于自愿披露公司产品列入WHO应急使用清单的公告。公告显示，公司产品猴痘病毒核酸检测试剂盒于2025年9月17日被列入世界卫生组织应急使用清单，申请号MPXV-13393-139-00，产品编码W-ZD-0580-02-48A、W-ZD-0580-02-96A，采购期限原则上为1年。列入EUL表明WHO对公司产品的认可，有助于产品在相关海外市场的推广和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800037888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765801158643,"stockEarnings":[{"period":"1week","weight":-0.0464},{"period":"1month","weight":-0.1097},{"period":"3month","weight":-0.2147},{"period":"6month","weight":0.1393},{"period":"1year","weight":0.08},{"period":"ytd","weight":0.2382}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海之江生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14435人(较上一季度减少7.74%)","perCapita":"13311股","listingDate":"2021-01-18","address":"上海市浦东新区张江高科技产业东区瑞庆路528号20幢乙号1层、21幢甲号1层","registeredCapital":"19215万元","survey":" 上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂和仪器设备。公司共有500多项产品，已形成20大系列，是国内感染性疾病分子诊断产品最为齐全的企业之一，覆盖了绝大多数国家法定传染病。","listedPrice":43.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"之江生物,688317,之江生物股票,之江生物股票老虎,之江生物股票老虎国际,之江生物行情,之江生物股票行情,之江生物股价,之江生物股市,之江生物股票价格,之江生物股票交易,之江生物股票购买,之江生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}